Every material Form 8-K IRulya Therapeutics Inc. has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IRulya Therapeutics posted an updated corporate presentation dated October 2026 on its investor website and furnished it as Exhibit 99.1 to this Form 8-K. The filing contains no financial results, guidance, or new financial statements; it describes the company's LAM-001 inhaled rapamycin programs and their expected timelines.
The presentation was posted October 19, 2026, and filed under Regulation FD, so it is not deemed filed under Section 18 of the Exchange Act.
The company lists LAM-001 Phase 2 data readouts: bronchiolitis obliterans syndrome (BOS) expected 1Q 2027, and PH-ILD Phase 2b expected 1Q 2028.
The presentation states the SAPH Phase 2 trial is expected to start in 4Q 2026, and that the Phase 2a PH-ILD 24-week results were presented at ATS in May 2026 with a 6MWD mean change of +81.3 meters in six evaluable patients.
Quince Therapeutics renamed itself IRulya Therapeutics effective October 9, 2026, following its merger with privately held Orphai Therapeutics. Brigette Roberts, M.D., was appointed Chief Executive Officer effective October 8, 2026, succeeding Dirk Thye, M.D., who resigned as CEO, Chief Medical Officer and director, and John Militello, CPA, and Keith Fandrick, Ph.D., were named Chief Financial Officer and Chief Operating Officer. The company's common stock is expected to begin trading on Nasdaq under the symbol IRLA on October 12, 2026.
Brigette Roberts, M.D., named CEO effective October 8, 2026, with an annual base salary of $600,000 and a target bonus of 50% of base salary
John Militello, CPA, named CFO with a $440,000 base salary; a restricted stock unit award for 80,000 shares is subject to Board approval
Keith Fandrick, Ph.D., named COO with a $450,000 base salary; Brendan Hannah resigned as COO, Chief Business Officer and Chief Compliance Officer
Cash balance of $116 million as of June 30, 2026, expected to fund operations through the end of 2028; common stock expected to be about 10,841,470 shares after Series C conversion
At a special meeting on October 6, 2026, stockholders approved raising authorized common stock from 250,000,000 to 275,000,000 shares and approved issuing common stock on conversion of Series C preferred stock and warrants, which the filing says could exceed 20% of outstanding shares and may, with management and board changes, result in a change of control. The filing body names Quince Therapeutics, Inc. while the header lists IRulya Therapeutics Inc., so the registrant identity should be confirmed. For shareholders, the approvals add capacity for potential dilution and a possible change in control.
Authorized common stock increased from 250,000,000 to 275,000,000 shares, effective October 6, 2026
Proposal 2 passed with 343,517 votes for and 5,759 against; Proposal 1 passed with 180,550 votes for and 5,742 against
Proposal 1 may result in a change of control under Nasdaq Listing Rule 5635(b)
2026 Equity Incentive Plan reserve starts at 821,872 shares; 2026 ESPP reserve starts at 142,045 shares
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IRulya Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →